Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment

• Status: Completed
• Trial end date: 2018-06-30
• Target enrollment: 0
• Participant gender: All

Summary

The HYGIA study was designed to investigate prospectively

1. the prognostic value of ambulatory blood pressure (BP) monitoring among subjects primarily evaluated at primary care settings

2. the impact of changes in ambulatory BP during follow-up in cardiovascular, cerebrovascular, metabolic, and renal risk in hypertensive patients

3. the influence of circadian time of treatment in cardiovascular, cerebrovascular, metabolic, and renal risk in hypertensive patients

4. the prevalence of an altered BP profile as a function of antihypertensive treatment, circadian time of treatment, age, and presence of diabetes, among other factors.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Vigo
• Collaborator: Servicio Gallego de Salud
• Treatments: Amlodipine; Antihypertensive Agents; Atenolol; Candesartan; Candesartan cilexetil; Carvedilol; Doxazosin; Enalapril; Enalaprilat; Irbesartan; Lercanidipine; Lisinopril; Manidipine; Olmesartan; Olmesartan Medoxomil; Quinapril; Ramipril; Telmisartan; Valsartan

Criteria

Inclusion Criteria:

• Male or female subjects ≥18 years of age.

• High-normal BP or essential hypertension.

• Any subject with recommendation for evaluation with ABPM according to the 2007 European Guidelines.

• Informed consent to participate in the study prior to any study procedures.

Exclusion Criteria:

• Known or suspected contraindications to any potential medication under investigation.

• Shift-workers.

• Inability to communicate and comply with all study requirements.

• Persons directly involved in the execution of this protocol.

• Intolerants to the use of the ABPM device.